Results

1–10 of 45 results for suprachoroidal

Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2023
Suprachoroidal Delivery of RGX-314 for Neovascular AMD Results of the Phase II AAVIATE Study
David S. Boyer, MD
Annual Meeting Talks
2023
Intraocular Pressure Elevation Immediately Following High-Volume (0.07 mL-0.15 mL) vs Standard Volume (0.05 mL) Injections
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2024
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Danny A. Mammo, MD
Annual Meeting Talks
2024
A Randomized Trial Comparing Suprachoroidal Injection of Triamcinolone and Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema
Murat Oncel, MD, FASRS
Annual Meeting Talks
2024
Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE® Study
Margaret A. Chang, MD, MS
Updates from the Field
2025
Suprachoroidal Hemorrhage
Retina Image Bank: Images of the Week
2024
Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2022
Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis
Christopher R Henry, MD
Annual Meeting Talks
2022
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2022